Innate Pharma (IPHA) Income from Continuing Operations (2019 - 2025)
Historic Income from Continuing Operations for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$25.6 million.
- Innate Pharma's Income from Continuing Operations rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$106.5 million, marking a year-over-year decrease of 1729.45%. This contributed to the annual value of -$52.9 million for FY2024, which is 54905.28% down from last year.
- Per Innate Pharma's latest filing, its Income from Continuing Operations stood at -$25.6 million for Q2 2025, which was up 193.0% from -$48.6 million recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Income from Continuing Operations ranged from a high of $7.5 million in Q2 2021 and a low of -$59.1 million during Q4 2022
- Over the past 5 years, Innate Pharma's median Income from Continuing Operations value was -$25.9 million (recorded in 2024), while the average stood at -$25.6 million.
- In the last 5 years, Innate Pharma's Income from Continuing Operations skyrocketed by 27442.65% in 2021 and then plummeted by 432199.99% in 2024.
- Innate Pharma's Income from Continuing Operations (Quarter) stood at -$47.5 million in 2021, then fell by 24.63% to -$59.1 million in 2022, then soared by 89.57% to -$6.2 million in 2023, then tumbled by 687.89% to -$48.6 million in 2024, then soared by 47.32% to -$25.6 million in 2025.
- Its last three reported values are -$25.6 million in Q2 2025, -$48.6 million for Q4 2024, and -$26.1 million during Q2 2024.